However, when we analyzed the non-treated SSc subgroup, we observed significant reduction of frequency of CD28 T cells in non-treated patients in comparison to controls (54.9 ± 21.4 vs. 73.6 ± 14.8, p < 0.01). This evidence concerns the gene CD28 and systemic sclerosis.